Tumor Biology

, Volume 35, Issue 6, pp 5945–5951 | Cite as

Do iron chelators increase the antiproliferative effect of trichostatin A through a glucose-regulated protein 78 mediated mechanism?

  • Veli Kilinc
  • Abdulkerim Bedir
  • Ali Okuyucu
  • Osman Salis
  • Hasan Alacam
  • Sedat Gulten
Research Article


Histone deacetylase (HDAC) inhibitors, such as trichostatin A (TSA), and iron chelators, including deferoxamine (DFO) and phenanthroline (PHEN), appear to have anticancer effects. We hypothesized that the HDAC inhibitors and iron chelators would be synergistic with their effect on breast cancer cell line MCF7, because the HDAC inhibitors increase glucose-regulated protein 78 (Grp78) and the iron chelators reduce its expression. Although the administration of TSA alone resulted in a dose-related decrease in the cell index, it did not have an antiproliferative effect except the 62.5 and 500 nM of TSA. However, all doses of TSA produced a cytotoxic effect from the initial hours when combined with 150 μM of DFO and 25 μM of PHEN. DFO and PHEN downregulated Grp78, Grp94, and MRP1 expressions and upregulated CHOP and HO-1 expressions. TSA upregulated all the genes in various rates when used alone but resulted in decreased expression levels when combined with DFO and PHEN. Increased HDAC-1 levels in the Grp78 promoter region indicated that DFO and PHEN either promoted binding of HDAC-1 to this region or inhibited its detachment. We determined that the reduction of increased Grp78, Grp94, HO-1, and MRP1 expressions, which appears to inhibit the chemotherapeutic effect of TSA, through the combination with DFO or PHEN will contribute to the anticancer effect.


MCF-7 Trichostatin A Deferoxamine Phenanthroline Grp78 CHOP 



This study was supported by the Ondokuz Mayis University. The project number was PYO.TIP. 1901 09 001.

Conflicts of interest



  1. 1.
    Yoshida M, Kijima M, Akita M, Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem. 1990;265:17174–9.PubMedGoogle Scholar
  2. 2.
    Yang XJ, Seto E. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene. 2007;26:5310–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Tsuji N, Kobayashi M, Nagashima K, Wakisaka Y, Koizumi K. A new antifungal antibiotic, trichostatin. J Antibiot (Tokyo). 1976;29:1–6.CrossRefGoogle Scholar
  4. 4.
    Wang JF, Bown C, Young LT. Differential display PCR reveals novel targets for the mood-stabilizing drug valproate including the molecular chaperone GRP78. Mol Pharmacol. 1999;55:521–7.PubMedGoogle Scholar
  5. 5.
    Zhang K, Kaufman RJ. The unfolded protein response: a stress signaling pathway critical for health and disease. Neurology. 2006;66:S102–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Li J, Lee AS. Stress induction of GRP78/BiP and its role in cancer. Curr Mol Med. 2006;6:45–54.CrossRefPubMedGoogle Scholar
  7. 7.
    Lee AS. GRP78 induction in cancer: therapeutic and prognostic implications. Cancer Res. 2007;67:3496–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Virrey JJ, Dong D, Stiles C, Patterson JB, Pen L, Ni M, et al. Stress chaperone GRP78/BiP confers chemoresistance to tumor-associated endothelial cells. Mol Cancer Res. 2008;6:1268–75.PubMedCentralCrossRefPubMedGoogle Scholar
  9. 9.
    Reddy RK, Mao C, Baumeister P, Austin RC, Kaufman RJ, Lee AS. Endoplasmic reticulum chaperone protein GRP78 protects cells from apoptosis induced by topoisomerase inhibitors: role of ATP binding site in suppression of caspase-7 activation. J Biol Chem. 2003;278:20915–24.CrossRefPubMedGoogle Scholar
  10. 10.
    Fu Y, Li J, Lee AS. GRP78/BiP inhibits endoplasmic reticulum BIK and protects human breast cancer cells against estrogen starvation-induced apoptosis. Cancer Res. 2007;67:3734–40.CrossRefPubMedGoogle Scholar
  11. 11.
    Pyrko P, Schonthal AH, Hofman FM, Chen TC, Lee AS. The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas. Cancer Res. 2007;67:9809–16.CrossRefPubMedGoogle Scholar
  12. 12.
    Ranganathan AC, Zhang L, Adam AP, Aguirre-Ghiso JA. Functional coupling of p38-induced up-regulation of BiP and activation of RNA-dependent protein kinase-like endoplasmic reticulum kinase to drug resistance of dormant carcinoma cells. Cancer Res. 2006;66:1702–11.PubMedCentralCrossRefPubMedGoogle Scholar
  13. 13.
    Hershko C. Control of disease by selective iron depletion: a novel therapeutic strategy utilizing iron chelators. Baillieres Clin Haematol. 1994;7:965–1000.CrossRefPubMedGoogle Scholar
  14. 14.
    Le NT, Richardson DR. Competing pathways of iron chelation: angiogenesis or anti-tumor activity: targeting different molecules to induce specific effects. Int J Cancer. 2004;110:468–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Miller MJ. Syntheses and Therapeutic Potential of Hydroxamic Acid Based Siderophores and Analogs. Chem Rev. 1989;89:1563–79.CrossRefGoogle Scholar
  16. 16.
    Darnell G, Richardson DR. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: the effect of the ligands on molecular targets involved in proliferation. Blood. 1999;94:781–92.PubMedGoogle Scholar
  17. 17.
    Belcher R. Application of chelate Compounds in Analytical Chemistry. Pure Appl Chem. 1973;34:13–28.CrossRefGoogle Scholar
  18. 18.
    Blatt J, Taylor SR, Kontoghiorghes GJ. Comparison of activity of deferoxamine with that of oral iron chelators against human neuroblastoma cell lines. Cancer Res. 1989;49:2925–7.PubMedGoogle Scholar
  19. 19.
    Hileti D, Panayiotidis P, Hoffbrand AV. Iron chelators induce apoptosis in proliferating cells. Br J Haematol. 1995;89:181–7.CrossRefPubMedGoogle Scholar
  20. 20.
    Ido Y, Muto N, Inada A, Kohroki J, Mano M, Odani T, et al. Induction of apoptosis by hinokitiol, a potent iron chelator, in teratocarcinoma F9 cells is mediated through the activation of caspase-3. Cell Prolif. 1999;32:63–73.CrossRefPubMedGoogle Scholar
  21. 21.
    Tanaka T, Satoh T, Onozawa Y, Kohroki J, Itoh N, Ishidate M, et al. Apoptosis during iron chelator-induced differentiation in F9 embryonal carcinoma cells. Cell Biol Int. 1999;3:541–50.CrossRefGoogle Scholar
  22. 22.
    Fu Y, Lee AS. Glucose regulated proteins in cancer progression, drug resistance and immunotherapy. Cancer Biol Ther. 2006;5:741–4.CrossRefPubMedGoogle Scholar
  23. 23.
    Jamora C, Dennert G, Lee AS. Inhibition of tumor progression by suppression of stress protein GRP78/BiP induction in fibrosarcoma B/C10ME. Proc Natl Acad Sci U S A. 1996;93:7690–4.PubMedCentralCrossRefPubMedGoogle Scholar
  24. 24.
    Wang Q, He Z, Zhang J, Wang Y, Wang T, Tong S, et al. Overexpression of endoplasmic reticulum molecular chaperone GRP94 and GRP78 in human lung cancer tissues and its significance. Cancer Detect Prev. 2005;29:544–51.CrossRefPubMedGoogle Scholar
  25. 25.
    Zheng HC, Takahashi H, Li XH, Hara T, Masuda S, Guan YF, et al. Overexpression of GRP78 and GRP94 are markers for aggressive behavior and poor prognosis in gastric carcinomas. Hum Pathol. 2008;39:1042–9.CrossRefPubMedGoogle Scholar
  26. 26.
    Dong D, Ni M, Li J, Xiong S, Ye W, Virrey JJ, et al. Critical role of the stress chaperone GRP78/BiP in tumor proliferation, survival, and tumor angiogenesis in transgene-induced mammary tumor development. Cancer Res. 2008;68:498–505.CrossRefPubMedGoogle Scholar
  27. 27.
    Lee AS. The glucose-regulated proteins: stress induction and clinical applications. Trends Biochem Sci. 2001;6:504–10.CrossRefGoogle Scholar
  28. 28.
    Reddy RK, Lu J, Lee A. The endoplasmic reticulum chaperone glycoprotein GRP94 with Ca2+-binding and antiapoptotic properties is a novel proteolytic target of calpain during etoposide-induced apoptosis. J Biol Chem. 1999;274:28476–83.CrossRefPubMedGoogle Scholar
  29. 29.
    Zhang L, Wang S, Wangtao, Wang Y, Wang J, Jiang L, et al. Upregulation of GRP78 and GRP94 and its function in chemotherapy resistance to VP-16 in human lung cancer cell line SK-MES-1. Cancer Investig. 2009;27:453–8.CrossRefGoogle Scholar
  30. 30.
    Liu M, Spellberg B, Phan QT, Fu Y, Fu Y, Lee AS, et al. The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice. J Clin Invest. 2010;120:1914–24.PubMedCentralCrossRefPubMedGoogle Scholar
  31. 31.
    Lovejoy DB, Richardson DR. Iron chelators as anti-neoplastic agents: current developments and promise of the PIH class of chelators. Curr Med Chem. 2003;10:1035–49.CrossRefPubMedGoogle Scholar
  32. 32.
    Baumeister P, Dong DZ, Fu Y, Lee AS. Transcriptional induction of GRP78/BiP by histone deacetylase inhibitors and resistance to histone deacetylase inhibitor-induced apoptosis. Mol Cancer Ther. 2009;8:1086–94.PubMedCentralCrossRefPubMedGoogle Scholar
  33. 33.
    Was H, Dulak J, Jozkowicz A. Heme oxygenase-1 in tumor biology and therapy. Curr Drug Targets. 2010;11:1551–70.CrossRefPubMedGoogle Scholar
  34. 34.
    Kim DH, Kim JH, Kim EH, Na HK, Cha YN, Chung JH, et al. 15-Deoxy-Delta12,14-prostaglandin J2 upregulates the expression of heme oxygenase-1 and subsequently matrix metalloproteinase-1 in human breast cancer cells: possible roles of iron and ROS. Carcinogenesis. 2009;30:645–54.CrossRefPubMedGoogle Scholar
  35. 35.
    Horndasch M, Lienkamp S, Springer E, Schmitt A, Pavenstadt H, Walz G, et al. The C/EBP homologous protein CHOP (GADD153) is an inhibitor of Wnt/TCF signals. Oncogene. 2006;25:3397–407.CrossRefPubMedGoogle Scholar
  36. 36.
    Kim DG, You KR, Liu MJ, Choi YK, Won YS. GADD153-mediated anticancer effects of N-(4-hydroxyphenyl)retinamide on human hepatoma cells. J Biol Chem. 2002;277:38930–8.CrossRefPubMedGoogle Scholar
  37. 37.
    Chang XB. A molecular understanding of ATP-dependent solute transport by multidrug resistance-associated protein MRP1. Cancer Metastasis Rev. 2007;26:15–37.CrossRefPubMedGoogle Scholar
  38. 38.
    Roy S, Kenny E, Kennedy S, Larkin A, Ballot J, Perez De Villarreal M, et al. MDR1/P-glycoprotein and MRP-1 mRNA and protein expression in non-small cell lung cancer. Anticancer Res. 2007;27:1325–30.PubMedGoogle Scholar
  39. 39.
    Baker EK, Johnstone RW, Zalcberg JR, El-Osta A. Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs. Oncogene. 2005;24:8061–75.CrossRefPubMedGoogle Scholar
  40. 40.
    Park HR, Tomida A, Sato S, Tsukumo Y, Yun J, Yamori T, et al. Effect on tumor cells of blocking survival response to glucose deprivation. J Natl Cancer Inst. 2004;96:1300–10.CrossRefPubMedGoogle Scholar
  41. 41.
    Yu DH, Macdonald J, Liu G, Lee AS, Ly M, Davis T, et al. Pyrvinium targets the unfolded protein response to hypoglycemia and its anti-tumor activity is enhanced by combination therapy. PLoS One. 2008;3:e3951.PubMedCentralCrossRefPubMedGoogle Scholar
  42. 42.
    Kurtoglu M, Gao N, Shang J, Maher JC, Lehrman MA, Wangpaichitr M, et al. Under normoxia, 2-deoxy-D-glucose elicits cell death in select tumor types not by inhibition of glycolysis but by interfering with N-linked glycosylation. Mol Cancer Ther. 2007;6:3049–58.CrossRefPubMedGoogle Scholar
  43. 43.
    Khaitan D, Chandna S, Dwarakanath SB. Short-term exposure of multicellular tumor spheroids of a human glioma cell line to the glycolytic inhibitor 2-deoxy-D-glucose is more toxic than continuous exposure. J Cancer Res Ther. 2009;5:S67–73.PubMedGoogle Scholar
  44. 44.
    Chang SH, Barbosa-Tessmann I, Chen C, Kilberg MS, Agarwal A. Glucose deprivation induces heme oxygenase-1 gene expression by a pathway independent of the unfolded protein response. J Biol Chem. 2002;277:1933–40.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Veli Kilinc
    • 1
  • Abdulkerim Bedir
    • 2
  • Ali Okuyucu
    • 2
  • Osman Salis
    • 2
  • Hasan Alacam
    • 2
  • Sedat Gulten
    • 2
  1. 1.Public Health LaboratoryKurupelitTurkey
  2. 2.Faculty of Medicine, Department of Medical BiochemistryOndokuz Mayis UniversitySamsunTurkey

Personalised recommendations